Symptomatic VMA treatment options

In the past, many eye care professionals chose to “watch and wait” to see whether the condition would go away on its own, which may sometimes occur, or they performed surgery.

JETREA® (ocriplasmin) injection, for Intravitreal Injection, 1.25 mg/mL: A nonsurgical treatment option

JETREA is the first and only FDA-approved
nonsurgical treatment option for symptomatic VMA
.15

  • Intravitreal injection—or injection into the vitreous of the eye—is a common way to deliver medication for eye conditions15
  • Alternative to surgery – injection takes a couple of minutes to administer

While JETREA does not work in everyone, it has been shown to be effective in causing the pulling on the macula to release.12,15 Your eye care professional will typically know within the first 7 days if JETREA has been effective.12,15

Speak to your eye care professional to see if an intravitreal injection is right for you and what you can expect from the injection. The intravitreal injection procedure may have associated effects inside the injected eye, such as inflammation, bleeding, or increased pressure.15

JETREA has been known to be effective and safe in many patients.12,15,16

Surgical treatment option

If your condition worsens, your physician may recommend a surgery called vitrectomy, a procedure that manually releases the macula’s attachment to the vitreous.

What to expect after JETREA treatment

As with any treatment, there may be a potential for side effects. Common side effects may include flashes of light in your vision, blurred vision, sensitivity to light, floaters that appear in your line of vision, or eye pain.15

Side effects may vary from person to person. Remember to report any symptoms or discomfort to your eye care professional as soon as possible.

Your eye care
professional can provide
you with more information
about the results you may
experience from treatment
with JETREA.


JETREA is intended to help release the attachment that is affecting your vision and may help resolve your eye condition and symptoms.15

As with any treatment, there may be a potential for side effects. Most side effects from JETREA are not serious, appear within 1 week after injection, and resolve within 2 weeks.17

Some side effects may include15:

  • Decreased vision
  • Blurred vision
  • Eye Redness
  • Flashes of light in your vision
  • Sensitivity to light
  • Floaters that appear in your line of vision
  • Eye pain

It is normal to experience such symptoms with an injection of this type. Therefore, do not drive or operate heavy machinery until visual impairment has stopped.

Side effects may vary from person to person. Remember to report any symptoms or discomfort to your eye care professionals as soon as possible.

Ask your eye care professional about whether JETREA is right for you.
Also learn if you may qualify for financial coverage for JETREA through the JETREA CARE® program.

Important Safety Information

Click to Expand
Indication

JETREA® (ocriplasmin) injection, for Intravitreal Injection, 1.25mg/mL is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Important Safety Information
Warnings and Precautions
  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).
Adverse Reactions
  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

To report SUSPECTED ADVERSE REACTIONS, contact ThromboGenics Inc. at 1-855-253-7396 [OPTION 2] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient.

References:
1. Sebag J, Wang M. Combined spectral-domain optical coherence tomography/scanning laser ophthalmoscopy imaging of vitreous and the vitreoretinal interface. In: Holz FG, Spaide RF, eds. Medical Retina: Focus on Retinal Imaging. Berlin, Germany: Springer-Verlag; 2010:157-168. 2. Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49(9):4089-4095. 3. Larsson L, Österlin S. Posterior vitreous detachment. A combined clinical and physiochemical study. Graefes Arch Clin Exp Ophthalmol.1985;223(2):92-95. 4. Meiss R. Sensory physiology. In: Rhoades RA, Tanner GA, eds. Medical Physiology. 1st ed. Boston, MA: Little, Brown and Company; 1995:61–89. 5. Fekrat S, Weizer JS. All About Your Eyes.Durham and London. Duke University Press; 2006:9. 6. Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567. 7. Jaffe NS. Vitreous traction at the posterior pole of the fundus due to alterations in the vitreous posterior. Trans Am Acad Ophthalmol Otolaryngol. 1967;71(4):642-652. 8. Smiddy WE, Michels RG, Glaser BM, deBustros S. Vitrectomy for macular traction caused by incomplete vitreous separation. Arch Ophthalmol. 1988;106(5):624–628. 9. Reese AB, Jones IS, Cooper WC. Macular changes secondary to vitreous traction. Trans Am Ophthalmol Soc. 1966;64:123–134. 10. Ezra E. Idiopathic full thickness macular hole: natural history and pathogenesis. 11. Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119(1)55-56. 12. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606-615. 13. Sonmez K, Capone A Jr, Trese MT, Williams GA. Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina. 2008;28(9):1207-1214. 14. Stalmans P, Lescrauwaet B, Blot K. A retrospective cohort study in patients with diseases of the vitreomacular interface (ReCoVit). Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting; May 4-8, 2014; Orlando, Florida. 15. JETREA [package insert]. Iselin, NJ: ThromboGenics, Inc.; 2017. 16. Ocriplasmin 2nd Periodic Benefit-Risk Evaluation Report. ThromboGenics NV. December 19, 2013. 17. JETREA summary of product characteristics. Iselin, NJ: ThromboGenics, Inc.; 02/2017.

Contact Us

Please fill out the form below.
* denotes a required field.